Skip to main content

Table 4 Use of resources and healthcare costs per patient/year of the series studied

From: Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Periods

Pretreatment (AAB)

Treatmenta

(AAB + AM)

Use of resources

 Medical visits (all)

15.4 (4.4)

13.4 (4.6)

 - Primary Care

12.1 (7.5)

10.6 (7.3)

 - Specialists

2.6 (4.3)

2.4 (3.0)

 - Hospital emergencies

0.7 (0.7)

0.4 (0.8)

 Laboratory

1.4 (1.6)

1.6 (1.7)

 Radiology

1.0 (1.9)

0.7 (1.2)

 Complementary tests

0.3 (0.9)

0.2 (0.5)

 Concomitant medicationb

19.1%

13.3%

 Pads

13.4%

9.7%

 Hospital stays

2.0 (7.7)

2.0 (6.1)

 Occupational disability, days

4.7 (17.9)

3.1 (17.1)

Costs (in €)

 Medical visits (all)

645 (460)

546 (420)

 Laboratory

32 (55)

35 (39)

 Radiology

19 (25)

13 (22)

 Complementary tests

20 (42)

17 (46)

 Hospital stays

750 (2.449)

746 (2.337)

 Specific medication

  Alpha-adrenergic blockers

195 (174)

190 (159)

  Antimuscarinics

398 (117)

 Concomitant medicationb

181 (99)

101 (75)

 Pads

82 (144)

47 (138)

Healthcare cost

1924 (2478)

1695 (2542)

Occupational disability cost

475 (1677)

316 (1744)

Total cost

2399 (3113)

2011 (3026)

  1. Values expressed as mean (SD: standard deviation) or percentage, p: statistical significance
  2. AAB alpha-blocker, AM antimuscarinic, euros
  3. aPeriod of combined treatment (12 months after the index date)
  4. bConcomitant medication (anxiolytics, antidepressants and antibiotics)
  5. Non-statistically significant difference when it is not indicated between the comparison by pairs (pretreatment vs. treatment), p < 0.001, p < 0.01